3 results
Approved WMOWill not start
Primary objectives* To determine the Overall Response Rate (ORR) in patients with (FGFR3MUT) advanced urothelial carcinoma treated with TKI258* To determine the Overall Response Rate (ORR) in patients with (FGFR3WT) advanced urothelial carcinoma…
Approved WMOCompleted
PrimaryTo assess the extended overall response rates of orally administered TKI258, at 500 mg/day, on a five days on and two days off dosing schedule, in groups of patients with relapsed or refractory multiple myeloma who are* with t(4;14)…
Approved WMOCompleted
To test the use of RFA and ER in a single endoscopic session in 20 consecutive patients with a BE containing visible abnormalities with HGD or EC upon biopsy.